Bone resorption and inflammatory inhibition efficacy of intermittent cyclical etidronate therapy in rheumatoid arthritis

Journal of Rheumatology

Volumn 30, Issue 3, 2003, Pages 474-479

  Hasegawa, Jun ^a   Nagashima, Masakazu ^a   Yamamoto, Munehiro ^a   Nishijima, Tohru ^a   Katsumata, Shinichi ^a   Yoshino, Shinichi ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

Deoxypyridinoline; Etidronate disodium; Interleukin 6; Larsen damage score; Osteoporosis; Rheumatoid arthritis

Indexed keywords

ALKALINE PHOSPHATASE; C REACTIVE PROTEIN; DEOXYPYRIDINOLINE; ETIDRONIC ACID; INTERLEUKIN 6;

ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BONE DENSITY; BONE DESTRUCTION; BONE MINERAL; CARTILAGE DEGENERATION; CELL ACTIVATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; FEMALE; FOLLOW UP; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; TREATMENT PLANNING;

AGED; ALKALINE PHOSPHATASE; AMINO ACIDS; ANTI-INFLAMMATORY AGENTS; ARTHRITIS, RHEUMATOID; BONE DENSITY; BONE RESORPTION; C-REACTIVE PROTEIN; ETIDRONIC ACID; FEMALE; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX;

EID: 0037333914     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Adachi JD, Bensen WG, Brown J, et al. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med 1997;337:382-7.
2. Roux C, Oriente P, Laan R, et al. Randomized trial of effect of cyclical etidronate in the prevention of corticosteroid-induced bone loss. J Clin Endocrinol Metab 1998;83:1128-33.
3. Cortet B, Hachulla E, Barton I, Bonvoisin B, Roux C. Evaluation of the efficacy of etidronate therapy in preventing glucocorticoid-induced bone loss in patients with inflammatory rheumatic diseases. Rev Rheum Engl Ed 1999;66:214-9.
4. Wimalawansa SJ. Combined therapy with estrogen and etidronate has an additive effect on bone mineral density in the hip and vertebrae: four-year randomized study. Am J Med 1995;99:36-42.
5. Katsumata T, Nakamura T, Ohnishi H, Sakurama T. Intermittent cyclical etidronate treatment maintains the mass, structure and the mechanical property of bone in ovariectomized rats. J Bone Miner Res 1995;10:921-31.
6. Adachi JD, Cranney A, Goldsmith CH, et al. Intermittent cyclic therapy with etidronate in the prevention of corticosteroid induced bone loss. J Rheumatol 1994;21:1922-6.
7. Geusens P, Dequeker J, Vanhoof J, et al. Cyclical etidronate increases bone density in the spine and hip of postmenopausal woman receiving long term corticosteroid treatment. A double blind, randomised placebo controlled study. Ann Rheum Dis 1998;57:724-7.
8. Jenkins EA, Walker-Bone KE, Wood A, McCrae FC, Cooper C, Cawley MID. The prevention of corticosteroid-induced bone loss with intermittent cyclical etidronate. Scand J Rheumatol 1999;28:152-6.
9. Sebaldt RJ, Adachi JD, Bensen WG, et al. Intermittent cyclic therapy with etidronate prevents corticosteroid-induced bone loss: two years of follow-up. Scand J Rheumatol 1996;25 Suppl 103:91-3.
10. Nishikaku F, Nakayama T, Nakatsuka M. Analgesic property of bisphosphonate, etidronate in animal models. Jpn Pharmacol Ther 1998;26:457-63.
11. Inoue T, Kusida K, Miyamoto S, et al. Quantitative assessment of bone density on X-ray picture. J Jpn Orthop 1983;57:1923-36.
12. Robins SP, Woitge H, Hesley R, Ju J, Seyedin S, Seibel MJ. Direct, enzyme-linked immunoassay for urinary deoxypiridinoline as a specific marker for measuring bone resorption. J Bone Miner Res 1994;9:1643-9.
13. Gomez B Jr, Ardakani S, Ju J, et al. Monoclonal antibody assay for measuring bone-specific alkaline phosphatase activity in serum. Clin Chem 1995;41:1560-6.
14. Larsen A, Dale K, Eek M. Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films. Acta Radiol Diagn 1977;18:481-91.
15. McCarty DJ. Methods for evaluating rheumatoid arthritis. In: Hollander JL, McCarty DJ, editors. Arthritis and allied conditions. A textbook of rheumatology. 8th ed. Philadelphia: Lea & Febiger; 1972:419-38.
16. Yamamoto I, Morita M, Taketani Y, et al. Evaluation of direct enzyme-immunoassay of urinary Dpd. Clin Endocrinol 1996;44:747-57.
17. Miki T, Nakatsuka Y, Ezawa K, Satoh K. Measurement of serum bone-ALP concentration with enzyme-immunoassay. Clin Endocrinol 1997;45:999-1004.
18. Masud T, Mulcahy B, Thompson AV, et al. Effects of cyclical etidronate combined with calcitriol versus cyclical etidronate alone on spine and femoral neck bone mineral density in postmenopausal osteoporotic women. Ann Rheum Dis 1998;57:346-9.
19. Jinnouchi Y. Efficacy of intermittent etidronate therapy for corticosteroid-induced osteoporosis in patients with diffuse connective tissue disease. Kurume Med J 2000;47:219-24.
20. Hall GM, Spector TD, Delmas PD. Markers of bone metabolism in postmenopausal women with rheumatoid arthritis. Arthritis Rheum 1995;38:902-6.
21. Eggelmeijer F, Papapoulos SE, van Paassen HC, Dijkmans BAC, Breedveld FC. Clinical and biochemical response to single infusion of pamidronate in patients with active rheumatoid arthritis: a double blind placebo controlled study. J Rheumatol 1994;21:2016-20.
22. Francis MD, Hovancik K, Boyce RW. NE-58095: a diphosphonate which prevents bone erosion and preserves joint architecture in experimental arthritis. Int J Tissue React 1989;11:239-52.
23. Bird HA, Hill J, Sitton NG, Dixon JS, Wright V. A clinical and biochemical assessment of etidronate disodium in patients with active rheumatoid arthritis. Clin Rheumatol 1988;7:91-4.
24. Nagaoka S, Motoji K, Hachiya M, Ounari K. Activity change of rheumatoid arthritis before and after etidronate administration. Clinical Calcium 1999;9:393-7.
25. Ralston SH, Hacking L, Willocks L, Bruce F, Pitkeathly DA. Clinical, biochemical, and radiographic effects of aminohydroxypropylidine bisphosphonate treatment in rheumatoid arthritis. Ann Rheum Dis 1989;48:396-9.
26. Giuliani N, Pedrazzoni M, Passeri G, Girasole G. Bisphosphonates inhibit IL-6 production by human osteoblast-like cells. Scand J Rheumatol 1998;27:38-41.
27. Olmos JM, De Vega T, Perera L, Riancho JA, Amado JA, Gonzalez-Macias J. Etidronate inhibits the production of IL-6 by osteoblast-like cells. Methods Find Exp Clin Pharmacol 1999;21:519-22.
28. Holt I, Cooper RG, Hopkins SJ. Relationship between local inflammation, interleukin-6 concentration and the acute phase protein response in arthritis patients. Eur J Clin Invest 1991;21:479-84.
29. Al-Awadhi A, Olusi S, Al-Zaid N, Prabha K. Serum concentration of interleukin 6, osteocalcin, intact parathyroid hormone, and markers of bone resorption in patients with rheumatoid arthritis. J Rheumatol 1999;26:1250-6.
30. Furumitsu Y, Inaba M, Yukioka K, et al. Levels of serum and synovial fluid pyridinium crosslinks in patients with rheumatoid arthritis. J Rheumatol 2000;27:64-70.